• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Neudexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • International Symposium
  • About
    • Who We Are
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

Neuronata-R/Lenzumestrocel

Background

Neuronata-R or Lenzumestrocel is an autologous bone marrow-derived mesenchymal stem cell product for treating Amyotrophic Lateral Sclerosis (ALS) developed by Corestem Chemon. Lenzumestrocel is administered via intrathecal injection and aims to slow ALS/MND progression by targeting neuroinflammation, promoting neuroprotection and preventing motor neuron death (Corestem Chemon website).

Lenzumestrocel was conditionally approved as on orphan drug for the treatment of ALS/MND by the South Korean Ministry of Food and Drug Safety (MFDS, Republic of Korea) in 2013, expecting the data to support a potential full approval in South Korea (Oh et al., 2015).

Approved In: Commercial Name:
South Korea NeuroNata-R

Proposed Mechanism of Action

Lenzumestrocel utilizes autologous bone marrow-derived mesenchymal stem cells (MSCs), which are adult stem cells capable of self-renewal and division. The treatment is prepared extracting bone marrow from the treated person, isolating and culturing the MSCs, and mixing them with cerebrospinal fluid (CSF – collected through spinal tap) from the same individual before administering the final product via intrathecal injection. The first injection of Lenzumestrocel typically occurs about four weeks after the initial bone marrow extraction, followed by a second injection four weeks later. The treatment is thought to target several biological pathways that may stimulate the growth of new nerve cells and regulate the immune response to damaged cells. Additionally, MSCs are thought to produce a range of molecules with modulatory effects, including the release of immune-modulating factors, putatively resulting in a protective effect on motor neurons through the expression of growth factors, and an anti-inflammatory effect (Corestem Chemon press release, Oh et al., 2018).

Clinical Trials

A phase 1 open-label trial assessed the safety and practicality of administering two intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (MSCs) over 12 months in eight people living with ALS/MND. Of the eight people, seven received intrathecal injections and one passed before the first administration. No serious adverse events were observed in the 12 month follow-up period (Oh et al., 2015).

Building on these results, a phase 2 randomized controlled trial with parallel groups (Clinicaltrials.gov ID: NCT01363401) was conducted in 64 participants with a 1:1 treatment to control ratio. Lenzumestrocel was considered safe and well tolerated and, when compared to the control group (n=27), people in the Lenzumestrocel treated group (n=32) showed smaller decline in their ALSFRS-R scores at the four-month (difference of 2.98; 95% CI 1.48–4.47, P < 0.001) and six-month (3.38; 95% CI 1.23–5.54, P = 0.003) marks, but no difference in the long term survival data (up to 75 months post treatment, Oh et al., 2018). Both of these trials allowed for participants to be treated with Riluzole.

In 2023, a long-term survival benefit study on 157 people within two years from diagnosis of ALS/MND and treated with Lenzumestrocel showed a higher survival probability when compared to placebo controls from the PROACT database (Nam et al., 2023). This study has a number of limitations and therefore the results from a phase 3 study are necessary to understand Lenzumestrocel’s efficacy in slowing the disease.

More recently, Corestem Chemon ran a phase 3 multicenter, randomized, double-blind, placebo-controlled trial involving 115 people living with ALS/MND (Clinicaltrials.gov ID: NCT01363401) to evaluate the safety and efficacy of Lenzumestrocel further. This study was designed to: 1) assess the long-term impact of two injections (single cycle) of Lenzumestrocel, with Group 1 receiving a single cycle at 26-day intervals 2) evaluate the long-term safety and effectiveness of multiple Lenzumestrocel injections, where Group 2 received the initial cycle followed by three additional injections spaced three months apart. A third group, Group 3 instead received the placebo injections. The primary outcome measures were monitoring of disease progression (as measured by combined assessment of function and survival, CAFS) at 6 months and 12 months as well as long term efficacy and safety evaluation up to 36 months (Nam et al., 2022). The study was run in five centers in South Korea, and, according to the Korea Biomedical Review website, the topline results from this trial showed no difference in disease progression for the groups treated with Lenzumestrocel when compared with placebo.

Dose and Administration

The dosage is 1.0 x 10^6 cells per kilogram of body weight, administered concurrently with Riluzole. The treatment involves intrathecal administration, with two injections given four weeks apart. Each pre-filled syringe contains 4.0 x 10^7 cells in 4 mL. The product should be stored in a cool place, between 2 and 8°C. The expiration date is 48 hours after manufacturing (Corestem Chemon website).

Reported Side Effects

There was no severe adverse drug reaction found during the safety assessment, lasting a year after the first administration.

Current Status

In 2023, a phase 2 study showed that two intrathecal injections of Lenzumestrocel, combined with Riluzole, slowed disease progression compared to placebo. However, given the small size of the trial, Corestem Chemon ran a phase 3 trial to evaluate its long-term safety and efficacy in people living with ALS/MND. The topline results from the Phase 3 clinical trial suggest that Lenzumestrocel may not have a strong clinical benefit. However, no peer review data was published, which makes interpretation of results challenging at this time.

Sources

Corestem Chemon website – https://corestemchemon.com/eng/business/business__product.html 

Oh et al., 2015 – https://pmc.ncbi.nlm.nih.gov/articles/PMC4449093/

Corestem Chemon press release – https://www.nature.com/articles/d43747-020-00727-8

Oh et al., 2018 – https://onlinelibrary.wiley.com/doi/10.1002/ana.25302

Nam et al., 2023 – https://pubmed.ncbi.nlm.nih.gov/37122380/ 

Nam et al., 2022 – https://pmc.ncbi.nlm.nih.gov/articles/PMC9115933/ 

Korea Biomedical Review – https://www.koreabiomed.com/news/articleView.html?idxno=26071 

International Alliance of ALS/MND Associations
February 2025


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • T Regulatory Cell Therapies
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Ann Nicol

    Ann Nicol

  • Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

    Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

  • Fabio Carvalho

    Fabio Carvalho

  • Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

    Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Alan Liz Ogg 29042016 000799 lo res

    Alan Liz Ogg 29042016 000799 lo res

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Ailsa Malcolm-Hutton, Diagnosed 2013,  MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013, MND Association of England, Wales and N Ireland

  • Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

    Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • IMG_2658

    IMG_2658

  • MNDaSG Group PALS & CALS, Motor Neurone Disease Association, Singapore (MNDaSG)

    MNDaSG Group PALS & CALS, Motor Neurone Disease Association, Singapore (MNDaSG)

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

    Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Ian Roberts

    Ian Roberts

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Conny van der Meijden, Diagnosed 2001,  ALS Netherlands

    Conny van der Meijden, Diagnosed 2001, ALS Netherlands

  • Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

    Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

  • Margarita Pizarro, Asociacion ELA Argentina, Diagnosed 2017, Argentina

    Margarita Pizarro, Asociacion ELA Argentina, Diagnosed 2017, Argentina

  • 83

    83

  • Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

    Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Jon Newsome, USA

    Jon Newsome, USA

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

  • Len Johnrose,  MND Association,  Diagnosed 2017,  England

    Len Johnrose, MND Association, Diagnosed 2017, England

  • March of Faces Photo Submission_ALEX_ELA ARGENTINA

    March of Faces Photo Submission_ALEX_ELA ARGENTINA

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

    Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

  • Calum Ferguson, Diagnosed 2010 , MND Scotland, UK

    Calum Ferguson, Diagnosed 2010 , MND Scotland, UK

  • Christian Bär, Germany

    Christian Bär, Germany

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

    Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

  • Josée Kolijn-de Man, Diagnosed 2015 , ALS Patients Connected, The Netherlands

    Josée Kolijn-de Man, Diagnosed 2015 , ALS Patients Connected, The Netherlands

  • Eddy LeFrançois, Diagnosed 1992,  ALS Canada

    Eddy LeFrançois, Diagnosed 1992, ALS Canada

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login